Riskpilot← Back to searchSign inGet full accessAspuddens Apotek AB
ABActiveOrg 5568609423Erik Segersälls Väg 5Retail sale of pharmaceutical products · NACE 4773Est. 20112 employees
Revenue 2024
SEK 10,2M
+10% vs 2023
EBITDA margin
5.4%
+24% vs 2023
Equity ratio
32.0%
Financial strength
Net profit 2024
SEK 361K
+16% vs 2023
| Revenue | SEK 10,2M | +10% |
| EBITDA | SEK 548K | +24% |
| Net profit | SEK 361K | +16% |
| Total assets | SEK 3,1M | +7% |
| Equity | SEK 978K | -1% |
| Employees | 2 | — |
Legal name
Aspuddens Apotek AB
Org number
5568609423
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
11 augusti 2011
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva försäljning av receptbelagda och receptfria läkemedel, samt övriga varor förenligt med verksamheten.
Address
Erik Segersälls Väg 5
Phone
+46739904547
Email
info@aspuddensapotek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 913 | 11 309 | 9 330 | 9 197 | 10 157 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 086 | 936 | 503 | 441 | 548 |
| Depreciation & amort. | −16 | −16 | −16 | −13 | −1 |
| EBIT | 1 070 | 920 | 487 | 428 | 547 |
| Net financials | — | — | — | 3 | 3 |
| Profit before tax | 949 | 794 | 467 | 400 | 466 |
| Tax | −210 | −168 | −101 | −90 | −105 |
| Net profit | 739 | 626 | 366 | 310 | 361 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 242 | 3 690 | 3 484 | 2 865 | 3 054 |
| Equity | 2 365 | 1 741 | 1 482 | 992 | 978 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 909 | 856 | 889 | 728 | 846 |
| Total debt | 909 | 856 | 889 | 728 | 846 |
EBITDA margin
5.4%
This company
15.8%
Market median
-66% vs market
20202024
Equity ratio
32.0%
This company
38.2%
Market median
+16% vs market
20202024
Return on equity
36.9%
This company
18.4%
Market median
+101% vs market
20202024
Net profit margin
3.6%
This company
8.1%
Market median
-56% vs market
20202024
Asset turnover
3.33×
This company
1.12×
Market median
+197% vs market
20202024
Debt / equity
2.12×
This company
0.62×
Market median
-242% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
OA Audit | Audit | 2022 |
LO Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aspuddens Apotek AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Olov Anders Slättås | Audit | 0 companies |
| Lana Obaid | Chief Executive Officer | 0 companies |
| Roland Tomas Karlsson | Deputy Board Member | 0 companies |